The exponential growth in the volume of information available on molecular structures and cellular function makes it difficult for researchers to assemble all the details into coherent models. New methodologies are needed to integrate, in one framework, information on genetic sequence polymorphisms along with their structural, functional, and dynamic/behavioral consequences. Although a fully accurate model is ideal, full details are not generally available and are gained only incrementally. Therefore, as a first step, we propose a knowledge model for the qualitative representation of the relationships between mutations and their effects at molecular, cellular, and clinical phenotypic levels. Our framework combines and extends two components: (1) a Workflow model that allows hierarchical process and participant specifications, (2) TAMBIS and the Unified Medical Language System, which serve as controlled biological and medical terminologies. By mapping our framework to Petri Nets, we can assess basic dynamic properties of biological models. Qualitative simulations using the compiled Petri Nets validate the model, and aid in predicting system behavior in the presence of dysfunctional components, and can be a step towards accurate quantitative models.
Introduction
Predicting pathological phenotypes based on genetic mutations remains a fundamental and unsolved issue. When a gene is mutated, the molecular functionality of the gene product may be affected and some cellular processes may go awry. Basic molecular functions occur in a network of interactions that produces subsequent cellular and physiological functions. Most knowledge of these interactions is represented diffusely in the published literature and so it is difficult to assess our state of understanding at any moment. Thus it would be very useful to systematically store knowledge in data structures that allow the knowledge to be systematically evaluated and examined be scientists as well as comp uter algorithms. Thus our goal is to develop technology for representing qualitative, noisy and sparse biological results in support of the eventual goal of fully accurate quantitative models.
In a recent paper, we described an ontology that we developed f or modeling biological processes [1] . Ontologies provide consistent definitions and interpretations of concepts in a domain of interest (e.g., biology), and enable software applications to share and reuse the knowledge consistently [2] . Ontologies can be used to perform logical inference over the set of concepts to provide for generalization and explanation facilities [3] . Our biological process ontology combines and extends two existing components: a Workflow model and a biomedicalontology, both described in the Methods and Tools section. Our resulting framework possesses the following properties: (1) it allows qualitative modeling of structural and functional aspects of a biological system, (2) it includes biological and medical concept models to allow for querying biomedical information using biomedical abstractions, (3) it allows hierarchical models to manage the complexity of the representation, (4) it has a sound logical basis for automatic verification, and (5) it has an intuitive, graphical representation.
Our application domain is tRNA-related disease. The main role of tRNA molecules is to be part of the machinery for the translation of the genetic message, encoded in mRNA, into a protein. This process employs over twenty different tRNA molecules, each specific for one amino acid and for a particular triplet of nucleotides in mRNA (codon) [4] . Several steps take place before a tRNA molecule can participate in translation. After a ge ne coding for tRNA is transcribed, the RNA product is folded and processed to become a tRNA molecule. tRNA molecules are covalently linked (acylated) with an amino acid to form amino-acylated-tRNA (aatRNA). The aa-tRNA molecules can then bind with translation factors to form complexes that may participate in the translation process. There are three kinds of complexes that participate in translation: (i) an initiation complex is formed by the binding of tRNA that is acylated with the amino acid formyl-methionine (fMet-tRNA) with guanidine triphosphate (GTP) and initiation factors, (ii) a termination complex is formed by binding Terminator tRNA (tRNA that binds to the stop codon in the mRNA template) with GTP and termination factors, and (iii) a ternary complex is formed by binding Elongating aa-tRNAs (tRNAs that are acylated to amino acids other than methionine and Terminator tRNA) with GTP and the elongation factor EF-tu. During the translation process, tRNA molecules recognize the mRNA codons one by one, as the mRNA molecule moves through the cellular machine for protein synthesis: the ribosome. In 1964,
Watson introduced the classical two-site model, which was the accepted model until 1984 [5] . In this model, the ribosome has two regions f or tRNA binding, so-called aminoacyl (A)-site and peptidyl (P)-site. According to this model, initiation starts from the P-site, but during the normal cycle of elongation, each tRNA enters the ribosome from the A-site and proceeds to the P-site before exiting into the cell's cytoplasm. Currently, it is hypothesized that the ribosome has at least three regions for tRNA binding: the A and P sites, and an exit site (E-site) through which the tRNA exits the ribosome into the cell's cytoplasm [6] . Protein synthesis is terminated when a stop codon is reached at the ribosomal A-site and recognized by a specific termination complex, probably involving factors mimicking tRNA. Premature termination (e.g., due to a mutation in tRNA) can be also observed [7] .
When aa-tRNA molecules bind to the A-site, they normally recognize and bind to matching mRNA codons -a process known as reading. tRNA mutations can cause abnormal reading that leads to mutated protein products of translation. Types of abnormal reading include: (1) Misreading, where tRNA with non-matching amino-acid binds to the ribosome's A -site, (2) frame-shifting, where tRNA that causes frame-shifting (e.g., binds to four nucleotides of the mRNA at the A-site) binds to the A-site, and (3) Halting, where tRNA that cause premature termination (e.g., tRNA that are not acetylated with an amino acid) binds to the A-site. These three types of errors can create a variety of phenotypes. Mutations in human tRNA molecules have been implicated in a wide range of disorders including myopathies, encephalopathies, cardiopathies, diabetes, growth retardation, and aging [8] . Development of models that consolidate and integrate our understanding of the molecular foundations for these diseases, based on available structural, biochemical and physiological knowledge, is therefore urgently needed.
The paper is organized as follows. Section 2 describes the components we used to develop the framework and the knowledge sources for our model. Section 3 discusses our modeling approach and demonstrates our knowledge model and the way in which information can be viewed and queried using the process of translation as examples. We conclude with a discussion and conclusion.
Methods and Tools

Component ontologies
Our framework combines and extends two existing components: Workflow model and biomedical ontology. The Workflow model [9] consists of a Process Model and an Organizational (Participants/Role) Model. The Process Model c an represent ordering of processes (e.g., protein translation) and the structural components that participate in them (e.g., protein). Processes may be of low granularity (high-level processes) or of high granularity (lowlevel processes). High-level processes are nested to control the complexity of the presentation for human inspection. The Participants/Role Model represents the relationships among participants (e.g., an EF-tu is a member of the Elongation Factors collection in prokaryotes) and the roles that participants play in the modeled processes (e.g., EF-tu has enzymic function: GTPase). A significant advantage of the workflow model is that it can map to Petri Nets [10] , a mathematical model that represents concurrent systems, which allows verification of formal properties as well as qualitative simulation [11] .
For the biomedical ontology, we combine the Transparent Access to Multiple Biological Information Sources (TAMBIS) [12] with The Unified Medical Language System (UMLS) [13] .
TAMBIS is an ontology for describing data to be obtained from bioinformatics sources. It describes biological entities at the molecular level. UMLS describes clinical and medical entities.
It is a publicly available federation of biomedical controlled-terminologies and includes a Semantic Network with 134 semantic types that provide a consistent categorization of thousands of biomedical concepts. The 2002AA edition of the UMLS Metathesaurus includes 776,940 concepts and 2.1 million concept names in over 60 different biomedical source vocabularies. We augmented these two core terminological models [1] to represent mutations and their affects on biomolecular structures, biochemical functions, cellular processes, and clinical phenotypes. The extensions include classes for representing: (1) mutations and alleles, and their relationship to sequence components, (2) nucleic acid 3D structure linked to secondary and primary structural blocks, and (3) a set of composition operators, based on the nomenclature of composition relationships, due to Odell [14] .
Odell introduced a nomenclature of six kinds of composition. We are using three of these composition relationships in our model. The relationship between a biomolecular complex (e.g., Ternary complex) and its parts (e.g., GTP, EF-tu, aa-tRNA) is a component-integral object composition. This relationship defines a configuration of parts within a whole. A configuration requires the parts to bear a particular functional or structural relationship to one another, as well as to the object they constitute. The relationship between an individual molecule (e.g., tRNA) and its domains (e.g., D -Domain, T -domain) is a place-area composition. This relationship defines a configuration of parts, where parts are the same kind of thing as the whole, and the parts cannot be separated from the whole. Member-bunch composition groups together molecules into collections when the collection members share similar functionality (e.g., elongation factors) or cellular location (e.g., membrane proteins). We have not found the other three composition relationships due to Odell to be relevant for our model. We implemented our framework using the Protégé-2000 knowledge-modeling tool. We used Protégé's axiom language (PAL) [15] to define queries in a subset of first-order predicate logic written in the Knowledge Interchange Format syntax. The queries present, in tabular format, relationships among processes and structural components, as well as the relationship between a defective process or clinical phenotype to the mutation that is causing it.
Translation into Petri Nets
We manually translated the tRNA workflow model into corresponding Petri Nets, according to mapping defined by others [11] . We upgraded the derived Petri Nets to Colored Petri Nets (CPNs), by:
(1) Defining color sets for tRNA molecules (mutated and normal), mRNA molecules, and nucleotides that comprise the mRNA sequence, and initiating the Petri Nets with an initial marking of colored tokens (2) Adding guards on transitions that relate to different types of tRNA molecules (e.g., fMettRNA vs. elongating tRNA molecules) (3) Defining mRNA sequences that serve as the template for translation
We used the Woflan Petri Net verification tool [16] to verify that the Petri Nets are bounded and live. To accommodate limitations in the Woflan tool, which does not support colored Petri Nets, we manually made several minor changes to the Petri Nets before verifying them. We simulated the Petri Nets to study the dynamic aspects of the translation process, using the Design CPN tool [17] .
Sources of biological data
We ga thered information from databases in order to develop the tRNA example considered in this work. We identified data sources with information pertaining to tRNA sequence, structure, mutations and disease associations. The databases that we used were:
• Compilation of mammalian mitochondrial tRNA genes [18] , aimed at defining typical as well as consensus primary and secondary structural features of mammalian mitochondrial tRNAs (http://mamit-trna.u-strasbg.fr/)
• Compilation of tRNA sequences and sequences of tRNA genes [19] (http://www.unibayreuth.de/departments/biochemie/sprinzl/trna/)
• The Comparative RNA Web site (http://www.rna.icmb.utexas.edu/), which provides a modeling environment for sequence and secondary structure comparisons [20] • Structural Classifications Of RNA (SCOR, http://scor.lbl.gov/scor.html) [21] • The RNA Modification Database (http://medlib.med.utah.edu/RNAmods), which provides literature and data on nucleotide modifications in RNA [22] • Plant mitochondrial tRNA genes and molecules (http://bio-WWW.ba.cnr.it:8000/srs6/) [8] • Online Mendelian Inheritance in Man (OMIM) (http://www.ncbi.nlm.nih.gov/omim/), which catalogues human genes and genetic disorders [23] • MetaCyc (http://ecocyc.org/ecocyc/). MetaCyc is a metabolic-pathway database, which describes pathways, reactions, and enzymes of a variety of organisms, with a microbial focus [24] .
• Entrez-Genomes database provides views for a variety of genomes, complete chromosomes, contiged sequence maps, and integrated genetic and physical maps (http://www4.ncbi.nlm.nih.gov/ entrez/query.fcgi?db=Genome) [25] .
• MITOMAP -A human mitochondrial genome database [26] (http://www.gen.emory.edu/mitomap.html)
Modeling Approach and Results
Our model represents data using Process Diagrams and Participant-Role Diagrams. Appendix A on our web site presents the number of processes, participants, roles, and links that we used in our model. The most granular thing that we represented was at the level of a single nucleotide (e.g., GTP). The biggest molecule that we represented was the ribosome. We chose our levels of granularity in a way that considers the translation process under the assumption of a perfect ribosome; we only considered errors in translation that are due to tRNA. This assumption also influenced our design of the translation process model. This design follows individual tRNA molecules throughout the translation process, and therefore represents the translocation of tRNA molecules from the P to E site, and from the A to P site as distinct processes that occur in parallel. The level of detail in which we represented the model led us to consider questions such as: (1) "Can tRNA bind the A-site before previously bound tRNA molecule is released from the E-site?", and (2) "Can fMet-tRNA form a ternary complex?".
Representing mutations
Variation in gene products (proteins or RNA) can result from mutations in the nucleotide sequence of a gene, leading to altered (1) translation, (2) splicing, (3) post-transcriptional endprocessing, or (4) interactions with other cellular components co-participating in biological processes. In addition, variation can result from a normal sequence that is translated improperly by abnormal tRNA molecules. Thus, we must be able to represent variation not only in DNA sequences (genome), but also in RNA and protein. Therefore, in our ontology, every Sequence_Component (of a nucleic acid or protein) may be associated with multiple Alleles.
Each Allele may have Mutations that are either pathogenic (associated with abnormal functions) or neutral. A mutation is classified as a substitution, insertion, or deletion [27] .
Representing nucleic acid structure
The TAMBIS terminology did not focus on 3D structure. We extended the TAMBIS ontology by specifying tertiary structure components of nucleic acids. A nucleic acid tertiary structure component is composed of interacting segments of nucleic acid secondary structure components.
We added three types of nucleic acid secondary structure components: nucleic acid helix, nucleic acid loop, and nucleic acid unpaired strand. Figure 1 shows the tertiary structure components of tRNA (Acceptor Domain, D-Domain, T-domain, Variable Loop, and Anticodon Domain). Also shown is the nucleic acid tertiary structure component frame that corresponds to the tRNA Acceptor Domain. The division of tRNA into structural domains, the numbering of nucleotides of the generic tRNA molecule, and the sequence-to-structure correspondence was done according to conventional rules [19] .
Representing molecular complexes
Biological function can be associated with different levels of molecular structure. In some cases a function can be associated with a domain (of a protein or nucleic acid). In other cases, a function is associated with individual molecules, or with molecular complexes. Some times, a function is not specifically mapped to a molecular structure, but is attributed to collections of molecules that are located in a particular cellular compartment. In addition, biologists define collections of molecules that share a common function (e.g., termination factors). The
Participant/Role representation of our framework represents molecular structures that participate in processes, as well as composition and generalization relationships among participants (molecules).
In our tRNA example, we are using three kinds of these composition relationships: (1) component-integral object composition, (2) member-bunch composition, and (3) place-area composition. Figure 2 shows examples of these relationships. Generalization (is-a) relationships are used to relate sub-classes of participants to their super-classes. For example, Terminator tRNA, Non-terminating tRNA, and fMet tRNA are sub-classes of the tRNA class.
Representing abnormal functions and processes
In addition to representing relationships among process participants, our framework can represent the roles that participants have in a modeled system. We distinguish two types of roles:
molecular-level functional roles (e.g., a role in translation) and roles in clinical disorders (e.g., the cause of cardiomyopathy). Each role is specified using a function/process code taken from the TAMBIS ontology. To represent dysfunctional molecular-level roles, we use an attribute, called role_present, which signifies whether the role is present, absent, or whether this information is unknown. For example, Figure 2 shows that three mutation of tRNA that exhibit the role of Misreading. The f igure also shows tRNA mutations that have roles in the cardiomyopathy disorder. Cardiomyopathy is one of the concepts from the clinical ontology, discussed later in this section.
Processes are represented using the Process Model component of our framework. Figure 3 . Figure 4 represents the translation process according to the classical twosite model [5] . Figure 5 represents a recent model of the translation process [28] . The details of the process of tRNA binding to A-site, of Figure 5 , are shown in Figure 6 .
The processes Normal reading, Misreading, Frame shifting, and Halting, shown in Figure 6 , all have a process code of Binding, since in all of them, tRNA binds to ribosome that has occupied E and P sites.
The types of arrows that connect molecules to a process define their role as substrates, products, inhibitors, activators, or mo lecules that participate without changing their overall state in the framework (e.g., enzyme). The logical relationships among participants are specified in a formal expression language. For example, double-clicking on the Misreading process, shown in Figure 6 , shows its participants, which are specified as:
((Shine dalgarno in E XOR tRNA0 in E) AND tRNA1 in P AND (tRNA2 that can bind to incorrect codon in Ternary complex XOR tRNA that has altered flexibility in Ternary complex) AND tRNA2 in A AND EF-tu AND GDP)
Representing high-level clinical phenotypes
Our clinical ontology relies on the UMLS, but does not include all of the concepts of the Metathesaurus. Instead, we are building our clinical ontology by importing concepts, as we need them. We add clinical concepts to the clinical ontology be creating them as subclasses of the semantic types defined by the Semantic Network. Each concept has a concept-name and a concept-code that come from the Metathesaurus, as well as synonyms. Figure 8 shows part of the clinical ontology. Figure 3 shows that mutated Leucine tRNA (in tRNA acceptor domain) and
Mutated tRNA (in T domain) have roles in some forms of cardiomyopathy.
Querying the model
Using PAL we composed first-order logic queries that represent in tabular form relationships among processes and structural components. Table 1 shows a summary of all the query types that we composed. They are grouped into six categories that concern: (1) alleles, (2) functional roles and roles in disorder phenotypes, (3) reactions and their participants, (4) biological processes, (5) ability to reach a certain state of a modeled system, and (6) temporal/dynamic aspects of a modeled system. Queries that were especially interesting to us were (1) finding mutations that cause molecular-level processes and functions to be dysfunctional, (2) finding mutations that cause clinical disorders, and (3) finding processes that might be affected in a given disorder. Figure 9 shows the query and query results for the third query.
Simulating the model
As shown in Figures 4 and 5 , we created two different models of the translation process: a historical model, and a current model. When we translated the workflow models into the corresponding Petri Nets, we were able to test predictions of these two models by showing that under certain concentrations of reactants, the different models resulted in different dynamic behavior, which produced different translation products. For example, when the mRNA contained a sequence of Asn-Leu-Asn (or in general, aa 1 -aa 2 -aa 1 ) and the system was initialized with a low concentration of Asn-tRNA, then protein translation proceeded in the classical twosite model but was halted in the current three-site model, which required Asn-tRNA and LeutRNA to be bound to the ribosome while a second Asn-tRNA bound the A-site. The Petri Net that corresponds to the workflow model of Figure 5 is shown in Figure 8 .
The Petri Nets derived from our workflow model can also be used for educational purposes.
They can demonstrate: (1) concurrent execution of low-level processes within the translation process (e.g., tRNA molecules that were incorporated into synthesized proteins can be amino acylated and used again in the translation process), (2) introduction of mutations into synthesized proteins, and (3) the affect of certain dysfunctional components on pools of reactants (e.g., nonmutated tRNAs).
Discussion
Deducing molecular mechanisms of disease based on molecular models is a very difficult problem. Even more complicated is the t ask of correlating genotypic variation to clinical phenotypes. A recent review by Florentz and Sissler [29] shows that, despite the accumulation of information about the positions of a large number of mutations within mitochondrial tRNAs, it is not possible to identify simple basic patterns for use in predicting the pathogenicity of new mutations. The authors conclude that it is critical to examine not only the affected tRNA, but also its interactions, or relationships, with other compartmental components. These arguments emphasize the importance of a knowledge model able to integrate practical information at multiple levels of detail and from multiple experimental sources.
The knowledge framework presented here links genetic sequence, structure and local behavior to high-level biological processes (such as disease). The model provides a mechanism for integrating data from multiple sources. In our tRNA example, we integrated information from structural biology, genetics, molecular biology, proteomics, and clinical science. The information can be presented graphically as Process Diagrams or Participant/Role Diagrams. The frames that represent participants, roles, processes, and relationships among them contain citations to the original data sources.
Our model has several advantages, in addition to its ability to integrate data from different sources. First, we can define queries that create views of the model in a tabular format. The queries extract useful relationships among structures, seque nces, roles, processes, and clinical phenotypes. Second, our model can be mapped in a straightforward manner to Petri Nets. We can thus use available tools to qualitatively simulate a modeled system and to verify its boundedness and liveness. Boundedness assumes that there is no infinite accumulation of tokens in any system state. In our example, this corresponds to concentration of tRNA and mRNA molecules in a cell.
Liveness ensures that all Petri Net transitions (which correspond to Workflow activities) can be traversed (enabled).
A disadvantage of our model is its need for manual data entry. Natural language processing techniques are not able to automatically parse scientific papers into the semantic structure of our ontology. The effort required to enter data into our model is considerable. The entry of a substantial set of data about all relevant cellular reactions and processes would require a major distributed effort by investigators trained in knowledge representation and biology.
Conclusion
Our long-term goal is to develop a robust knowledge framework that is detailed enough to represent the phenotypic effects of mutations in tRNA molecules. The results presented here are a first step in which we demonstrate that the knowledge model developed i n another context Yes. It inhibits the process "Formation of initiation complex" which is essential to take place before Translation.
Establish a marking, find reachability
Elongating tRNA is a substrate. What pathways will be taken? Amino acid acylation, followed by Formation of Ternary complex, followed by Translation. 6. Temporal/dynamic aspects 6.1 What other processes occur in parallel to processX?
What processes occur in parallel to "Binding to A-site" (Figure 6) "shine dalgarno exits" XOR "tRNA1 exits" Figure 1 . Representing tertiary structure components. Normal tRNA is composed of five nucleic acid tertiary structure components. One of these components (tRNA Acceptor Domain) is shown in the middle frame. Each nucleic acid tertiary structure component is composed of segments of nucleic acid secondary structure components. The nucleic acid unpaired strand of the tRNA Acceptor Domain, which is a kind of nucleic acid secondary structure components, is shown on the right. Figure 2 . Part of the Participant/Role diagram showing molecules involved in translation and the roles that they fulfill. Individual molecules are shown as rectangles (e.g., tRNA). They are linked to domains (e.g., D-Domain) using dashed connectors. Biomolecular complexes are shown as hexagons (e.g., Ternary Complex), and linked to their component molecules using arrowhead connectors. Collections of molecules that share similar function or cellular location are shown as triangles (e.g., Elongation factors) and are linked to the participants that belong to them using connectors with round heads. Generalization relationships are shown as dotted lines (e.g., fMettRNA is-a tRNA). Functional roles are shown as ellipses that are linked to the participants that exhibit those roles. Clinical disorders that are associated with mutated participants are shown as diamonds (e.g., Cardiomyopathy) and are linked to the participants that exhibit roles in these disorders. The insert shows the details of the Misreading role. It is specified as Translation role (TAMBIS class) that is not present (role_present = false). Also shown are some of the participants that perform the misreading role. according to the classical two-site model [5] . The symbols are as explained in the legend of Figure 3 . After initiation, there is an aa-tRNA in the P-site (tRNA1 in P). During the "Binding to A-site and peptide bond formation" process a second aa-tRNA in ternary complex binds to the A-site. Two processes occur simultaneously at the next stage: movement of the second tRNA that bound to the A-site to the P-site, and at the same time, exit from the ribosome of the first tRNA that bound to the P-site. If the second tRNA, bound to the P-site, is of terminator type, termination occurs. Otherwise, the ribosome is ready to bind; the second tRNA to bind tRNA is now labeled as "tRNA1 in P" and another cycle of elongation can begin. Figure 4 , according to the model of Connell and Nierahus [28] . The details of the process "Binding of tRNA to A-site" are shown in Figure 6 . After initiation, shine dalgarno is placed at the E site, and the first tRNA (tRNA1) is placed at the P site. Next, tRNA2 transiently binds to the A-site. This step is followed by three activities which are done concurrently: (1) exit from the E-site, of either shine dalgarno or a tRNA bound to the E-site (at later stages of the elongation process), (2) binding to A-site followed by peptide bond formation, and (3) a routing activity (marked by an unlabeled round-corner square). The routing activity is needed for correspondence with the colored Petri Net that simulates the translation process, which needs to distinguish among the tRNA molecules that are bound to each of the three sites. At the next stage, the tRNA at the A site shifts to the P site, and at the same time, the tRNA at the P site shifts to the E site. If the tRNA bound to the P-site is of terminator type, termination occurs. Otherwise, the ribosome is ready to bind; the second tRNA to bind is now labeled as "tRNA1 in P", and the first tRNA to bind is labeld as "tRNA0 in E", and another cycle of elongation can begin. have roles that are disorders, and (2) have roles that are dysfunctional processes or functions. Transitions are also labeled t6..t15, in correspondence with query 5.2 of Table 1 .
